NCT00118092View on ClinicalTrials.gov

17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy

PHASE2CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

February 29, 2008

Conditions
Adenocarcinoma of the ProstateRecurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

tanespimycin

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

55905

Mayo Clinic, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00118092 - 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy | Biotech Hunter | Biotech Hunter